Category: Health
The biotechnology company GeoVax Labs, Inc. has reportedly announced to have joined hands with the pharmaceutical firm Enesi Pharma to develop needle-free solid-dose vaccine formulations by using its unique Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform along with Enesi’s ImplaVax® device and formulation technology. …
The outcome of the Vectra(R) clinical studies were published in the journal Rheumatology. The adjusted Vectra(R) test is significantly more effective than conventional methods in predicting radiographic progression in individuals suffering from Rheumatoid Arthritis. Myriad Genetics, Inc. (Myriad), a leading American molecular diagnostic firm, has …
By signing a collaboration deal with Agenus, Gilead is continuing to foray into the field of cancer immunotherapy. The partnership aims to develop & commercialize around five new immuno-oncology (I-O) treatments. Gilead Sciences, Inc., (Gilead), a renowned American biotechnology company, has reportedly announced that it …
Glenmark’s branded portfolio will be developed and commercialized under the subsidiary Glenmark Therapeutics Inc., USA. Renowned pharmaceutical firm, Glenmark Pharmaceuticals has recently announced that its wholly owned subsidiary, Glenmark Therapeutics Inc., USA, will enter the branded dermatology segment in the United States. This will be …
Cannabis firms Aleafia Health Inc. and Emblem Corp. have recently announced that they have inked a definitive agreement according to which, Aleafia would acquire all of the issued and common shares of Emblem in an all-share transaction. The deal, to proceed as per a plan …
The acquisition will help Merck gain access to a broader customer base and enhance its Animal Health segment Renowned pharmaceutical company, Merck & Co., Inc., has recently announced that it has reached a definitive agreement to acquire all unresolved shares of French animal health firm, …
Forbion, a healthcare venture capital firm with centers in Germany and the Netherlands, recently announced that its portfolio company Staten Biotechnology B.V. and Denmark-based healthcare company Novo Nordisk A/S have collaborated and signed an exclusive option agreement in a bid to develop new therapeutics hypertriglyceridaemia …
Reports confirm that pharmaceutical company Novartis has withdrawn its application for marketing the drug canakinumab in Europe. The drug was aimed at preventing serious incidents like myocardial infarction (MI), stroke and death in patients that earlier had an MI. Apparently, this move came just a …